← Back to all trials
Recruiting
NCT07227805
Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS)
Conditions: Diabetes (Insulin-requiring, Type 1 or Type 2)
Sex: All
Ages: 2 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 116
Sponsor: Medtronic MiniMed, Inc.
Location: Universitair Ziekenhuis Antwerpen Antwerp
Summary
This study will demonstrate the safety and performance of the Novel Medtronic Experimental Automated Insulin Delivery system named MiniMed™ NMX8 system in people living with insulin-requiring diabetes in comparison with the MiniMed™ 780G system.
Eligibility Criteria
Inclusion Criteria:
1. Is aged ≥2 years old at time of screening.
2. Has a clinical diagnosis of Type 1 or Type 2 diabetes for ≥ 6 months prior to screening as determined via medical record by an individual qualified to make a medical diagnosis.
3. Is on MiniMed™ 780G with Simplera Sync sensor for at least 3 months before screening.
4. Has a glycosylated hemoglobin (HbA1c) \
Source: ClinicalTrials.gov (NCT07227805). StuddyBuddy aggregates publicly available trial information.
